Description: Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.
Home Page: www.ternspharma.com
TERN Technical Analysis
1065 East Hillsdale Boulevard
Foster City,
CA
94404
United States
Phone:
650 525 5535
Officers
| Name | Title |
|---|---|
| Mr. Senthil Vel Sundaram | CEO & Director |
| Dr. Erin Quirk M.D. | Pres & Head of R&D |
| Mr. Seokho Yoon Esq. | COO, Gen. Counsel & Sec. |
| Dr. Weidong Zhong Ph.D. | Co-Founder & Exec. Officer |
| Dr. Mark Joseph Vignola | CFO & Treasurer |
| Dr. Jeffrey R. Jasper Ph.D. | Sr. VP & Head of Research |
| Ms. Diana Chung | Sr. VP & Chief Devel. Officer |
| Dr. Kerry Russell M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3392 |
| Price-to-Sales TTM: | 256.5261 |
| IPO Date: | 2021-02-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |